ClinicalTrials.gg
Not yet recruitingNCT07945093DIMEUpdated Nov 18, 2026

Diabetes Insulin Self-Management Education (DIME) Web-based Application to Support People With Type 2 Diabetes (T2D) Starting Insulin in Hospital

An observational study in Type 2 Diabetes, Insulin and Education, sponsored by King's College London. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by King's College London · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
10
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom — 58 open to participants now, 74 under way, 20 of them phase 3. Diabetes Mellitus, Type 2 · United Kingdom.

Planned enrollment
75th of 78
10 · median 578
Started
2026
with 21 others
Observational
78 of 573
17 open now
Primary completion
2027-06
later than 36 of 73 live
Registered
571st of 573
by date

Among the 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, this one is the 75th largest by planned enrollment of the 78 observational ones that give a count, is one of 22 that started in 2026, is one of 78 observational ones, reaches primary completion later than 36 of the 73 other live ones, and was the 571st registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

58 of the 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of this study is to find out the views of nurses and inpatients with type 2 diabetes of the Diabetes Insulin self-Management Education (DIME) web-based application. DIME was developed by nurses and people with type 2 diabetes, and a prototype was developed. The DIME app has been developed over a long period of time in response to the needs and concerns of people with type 2 diabetes starting insulin and a pilot study which led to the development of the original DIME programme. The current study involves introducing the DIME app to a small number of people starting insulin in hospital and the nurses who educate them and interviewing them about their thoughts on using it. The investigators will also count the number of people with type 2 diabetes who start insulin in hospital and the main reason for starting it over a 6 month period.

This project will help us to understand if a digital tool such as DIME might help to support in hospital insulin starts. The investigators will also know how many people are likely to need the support as they will have counted the number of people starting insulin when they have type 2 diabetes in hospital over a 6 month period. It will involve patients and nurses. The nurses involved will understand how, what, when, and why new technology such as the DIME app can fit within the hospital setting.

The study has been designed to address the following questions:

What are the views of people living with type 2 diabetes and nurses on the use of a web-based app to support in-hospital insulin starts? How many people with type 2 diabetes start insulin in hospital over a 6 month period and what is the reason for starting it?

Read the detailed description

Introduction In 2021-22, there were 3.4 million adults living with type 2 diabetes (T2D) in England. Because this figure continues to rise while the age of T2D onset decreases concurrently, people have begun to live longer with diabetes and will likely need insulin to avoid micro-vascular complications. Insulin is a high-risk medication, presenting possible complications for people with T2D, and can be complex for healthcare professionals (HCP) to manage and support people with T2D. Current T2D NICE guidance suggests that insulin be used for individuals with an HbA1c ≥ 58 mmol/mol on 2 or more oral agents. Many people with T2D do not want to take insulin, an inclination exacerbated by the health system and how HCPs respond to people who need it. Even when people start insulin, 30-50% are not optimised in terms of achieving target glycaemia. In the community, a high proportion refuse to start insulin; consequently, they become unwell, are hospitalised, and initiate insulin in hospital. There are anecdotally 40-60 insulin starts per month at King's College Hospital but this figure needs to be confirmed, while there are 75% fewer in community clinics, where insulin initiation programmes have typically been run.

In many situations in which a patient does initiate insulin in hospital, they frequently receive instruction on injection techniques in a time-pressured situation. Nurses typically have around 30 minutes to complete the demonstration and patients may be left with an incomplete understanding about insulin or feel that their questions went unanswered. Additionally, nurses have expressed concern that they will forget to pass on important information that could cause harm to the patient. Digital resources such as web-based applications, however, offer a promising means by which patients can be supported with in hospital insulin initiation. Web-based resources can be easily accessed by mobile phone, tablet or PC and can provide a back-up if patients are discharged sooner than expected, with trusted information to refer back to.

In a previously written systematic review and meta-analysis of insulin education programmes, the investigators demonstrated that insulin education employing psychological techniques led to better glycaemic control. The findings were incorporated into a group-based Diabetes Insulin self-Management Education (DIME) programme, which was tested in community diabetes clinics. However, as fewer patients are seen in community clinics, attendance at education is low; because DIME required staff training, DIME was re-developed as a web-based application.

RATIONALE The aim of this project is to determine the views of nurses and inpatients with T2D of the DIME web-based application. DIME was co-designed and co-produced by nurses and people with T2D (manuscript in preparation), and a prototype was developed. The DIME web-based application is underpinned both by a previous qualitative study involving people with T2D who had recently started insulin, in addition to a pilot RCT which led to the development of the original DIME programme. The current project involves introducing the DIME web-based app resource with a small sample of people starting insulin in hospital and the nurses who educate them and interviewing them about their thoughts on using it. Concurrently, the number of people with T2D who start insulin in hospital will be counted and the main reason for starting it.

This project will help us to understand if a digital resource might help to support in hospital insulin initiation and determine the scale of the problem. It will therefore involve patients and nurses. The nurses involved will understand how, what, when, and why new technology such as the DIME digital assistant can fit within this complex clinical setting.

The study has been designed to address the following question:

What are the views of people living with T2D and nurses on the use of a web-based app to support in-hospital insulin initiation? How many people with T2D start insulin in hospital over a 6 month period and what is the reason for starting it?

Study Purpose and Objectives This is a non-commercial study.

Primary Objectives

  • To interview people living with type 2 diabetes in hospital about their views on using a web-based app to support initiation of insulin treatment.
  • To interview hospital nurses/diabetes nurses to determine their views about the web-based app.
  • To determine the number of people with T2D starting insulin over a 6 month period and the reason for starting it.

Study Design To determine stakeholder views of the DIME web-based resource, this qualitative phase involves semi-structured interviews with people with T2D who started insulin in hospital, inpatient and diabetes nurses. There will also be an audit of the number of people with T2D starting insulin in hospital over a 6 month period and the reason for this.

Study Setting King's College Hospital is a large teaching hospital in south London with a large number of diabetes inpatients. Individual semi-structured interviews with 6-12 people with T2D who started insulin as an inpatient at King's College Hospital will be conducted. Consecutive convenience sampling will be used for this. Concurrently, individual semi-structured interviews with 4-6 inpatient and diabetes nurses will be conducted.

Participant selection Semi-structured interviews: adults aged 18 and above with T2D diagnosis who started insulin as an inpatient at King's College Hospital and willing to give their views on the DIME web-based app. Inpatient and diabetes nurses at King's College Hospital caring for people with T2D starting insulin in hospital and willing to give their views on DIME web-based app.

Observational study: number of people with T2D who start insulin in hospital will be counted and coded according to the reason they started insulin, i.e. acute hyperglycaemia, infection, MI, CVA etc

Participant inclusion criteria

Interview study:

Patient Participants:

  • Adults aged 18 and above.
  • Adults with a type 2 diabetes diagnosis.
  • Adults who started insulin as an inpatient
  • Adults who understand and can communicate in English.
  • Adults who have the capacity to consent.

Nurse Participants:

  • Diabetes nurses working at King's College Hospital NHS Foundation Trust
  • Inpatient nurses caring for people with T2D

Participant exclusion criteria

  • Adults who are not willing to participate.
  • Adults with severe physical/mental illness or cognitive dysfunction/significant learning difficulties.
  • Adults who are unable to speak or understand English

Study procedures Participant recruitment Patient participants will be identified by their usual clinical care teams working at King's College Hospital. If eligible for the study, nurses who work in these settings will inform participants who meet the inclusion criteria of the study, and with their expressed interest and consent, introduce them to a researcher who will talk to them and give them the participant information sheet explaining the purpose of the study.

No one outside the direct care team will require access to the medical records of the participants.

Nurse participants will be invited to participate in the interviews by the Chief or Principal Investigator. If they are interested and provide consent, they will be informed of the study and given an opportunity to ask questions.

The number of people with T2D starting insulin in hospital will be collected by King's College Hospital diabetes nurses.

Screening Procedures Potential patient participants will be approached by diabetes healthcare professionals. The clinicians will invite potential participants and ask if they can give permission for the researchers to contact them. Alternatively, the clinicians will obtain consent from potential participants to pass on their contact details to the researchers should they express interest in participating.

Potential nurse participants will be approached to participate in the interviews with the Chief Investigator.

Schedule of Assessments for Each Visit Following consent being obtained the interviews will be conducted at the participants' choice of time/date. This could be on the same day as taking consent if this is convenient to the participant.

End of Study Definition For interview participants participation ends following the interview. The end of the study in its entirety will by at 6 months from study start to ensure the numbers of people starting insulin over a 6 month period are counted.

Data Collection Procedures The primary goal of the analysis will to be to identify participant views of the DIME web-based app. Recorded interviews will be transcribed verbatim and related files will be managed using NVivo software.

The second part of the analysis will be to count the number of people with T2D starting insulin in a 6 month period as inpatients in King's College Hospital. This data will be collated via the diabetes nurse team at King's College Hospital.

Data Recording/Reporting Results of the study will be reported in peer reviewed publications and used in subsequent grant applications. Participants who complete the interviews will have the opportunity to review their own transcripts.

Data Transfer to sites outside the Organisation No data will be transferred outside of KCL.

Data storage Data files/transcripts will be pseudoanonymised and stored on password protected KCL Cloud.

Regulatory Approvals The study protocol and other documentation will be submitted to the [state the name and address of the REC] before the start of the study.

Amendments Amendments will be submitted to the relevant regulatory bodies for review following sponsorship approval. Amendments will not be implemented without the required regulatory and site approvals in place, as determined by the HRA. Correspondence with the sponsor, REC and HRA will be retained.

End of Study Reporting End of Study Declaration The end of the study will be declared to the REC within 90 days of the study ending.

End of Study Reporting The end of the study report will be submitted to the REC within 12 months of the study ending.

Ethical considerations No major risk to the participants in the context of this study are anticipated. The study does not involve any invasive or ethically contentious activities. However, the focus of the study may raise issues for participants that could potentially raise emotional reactions. The research team has a high level of expertise in caring for this population and managing psychological distress, therefore we are confident that we will be to manage this sensitively and provide patients with any follow-up intervention they may need from the clinical team. If any concerns about participants are identified, appropriate action or referral shall be taken with the participating clinicians, and, where indicated, the local safe-guarding officer. Any adverse events arising in the conduct of the study will be recorded, reported to the principle and clinical investigator.

Potential benefits for adults with T2D includes the opportunity to speak about their experiences of using insulin to manage T2D. This may prove psychologically beneficial by offering peer support, feelings of empowerment with regards to informing new ways in which digital technology can support hospital insulin initiation. Additionally, participants may have the opportunity to use DIME in the future should it be made available.

Potential benefits of this project for nurses includes empowering nurses by looking to identify how digital technology can solve some of the current problems faced by diabetes nurses supporting people with T2D starting insulin in hospital. This project is nurse-led.

Safety \& Adverse Events Reporting An Adverse Event (AE) is any untoward medical occurrence in a participant that occurs as a result of the patient's involvement in the study.

A Serious Adverse Event (SAE) is an AE that results in one or more of the following:

  • death
  • a life-threatening state or condition
  • hospitalisation or prolonged hospitalisation
  • persistent or significant disability or incapacity
  • congenital abnormality or birth defect

No SAEs are expected as a result of this study. AEs that could occur might include distress about discussing diabetes treatment

Compliance and withdrawal Withdrawal/ drop out of participants Participants who have conducted the interview may withdraw from the study without giving a reason and their data will be destroyed up to the point at which the study report is written, within 3 months of their participation from the date on the consent form.

Protocol Compliance Deviations to the protocol will be documented and reported to the sponsor. Data Data to be collected

Qualitative data collection will involve 1 interview per participant following informed consent:

  • Data to be collected is mainly via semi-structured interviews, regarding views of the DIME web-based app, which will be transcribed and analysed

Other data:

  • Numbers of people with T2D starting insulin in hospital over 6 month period and main reason for this, such as: hyperglycaemia, infection, MI, CVA. Data would be anonymous.

Data handling and record keeping Semi-structured interview data will be recorded using an encrypted audio-recorder or via MS Teams. Data will be transcribed using a university approved transcriber or by the research team.

Interview transcripts will be pseudo anonymised.

Records retention and archiving, data to be kept for 5 years and stored on KCL Cloud via password protection.

No personal information will be kept once study reports prepared/published.

UK General Data Protection Regulation and Data Protection Act 2018 will be adhered to.

Access to the dataset Only the principal investigator, chief investigator and research assistant will have access to the data. University approved transcription service may be used and have access to pseudonymised transcript data.

Data considerations No statistician as this is a qualitative study Sample size calculation As this is a qualitative study, the concept of information power will be used to determine the sample size. This is dependent on the depth of information gleaned from the interviews, the more depth the fewer interviews required as well as whether the aims and objectives of the study are met (12). Therefore, the aim is to interview 4-6 nurses and 6-12 people with T2D.

Data analysis

The primary goal of the analysis will to be to identify participant views of the DIME web-based app. Recorded interviews will be transcribed verbatim and related files will be managed using NVivo software. Transcripts will be analysed using framework analysis. Framework analysis involves 5 stages: 1) familiarisation and close reading of interview transcripts and audio-files; 2) generation of initial codes and a thematic framework by two researchers independently; 3) indexing and applying the framework to the dataset; 4) charting of the data; 5) mapping and interpretation of the framework to the coded data.

The second part of the analysis will be to count the number of people with T2D starting insulin in a 6 month period as inpatients in King's College Hospital. This data will be collated via the diabetes nurse team at King's College Hospital.

Risk Management \& Safeguarding For the participants taking part in the interviews and workshops, the opportunity to share their own experiences, listen to others and relate to common experiences may be psychologically beneficial and offer people various perspectives of diagnosis and adaptation to life with diabetes. However, for some, the narrative of their own experience or that of others may induce feelings of discomfort, distress or anxiety which might not have been expressed previously. The researcher will aim at minimizing this risk by being mindful of potential reactions during the data collection process. This will be done by developing an interview guide on the basis of a literature review and asking the patients in the advisory group for comments. Also any signs of distress or anxiety exhibited by the participants will be addressed and they will be offered the chance to terminate the interview. They will be referred to appropriate follow-up and given contact details for additional support.

The lead researcher is an experienced clinician and has experience in conducting interviews. These skills will also be utilized where appropriate during the interaction with the participants.

All the researchers involved in the study will have safe-guarding training and will adhere to the safeguarding policies of KCL and the participating NHS Trust. Any adverse occurrences that occur during the study will be logged and reported to the PI and CI for appropriate action. They will also be presented anonymously to the advisory board.

It is not thought that there are any risks to researchers in excess of those already posed to them as clinicians working in a hospital setting.

Another risk is that of data protection and security. All personal data will be kept confidential in line with NHS Code of Confidentiality. Contact details (email, telephone numbers, and/or addresses) of participants will be kept in a file, in a locked filing cabinet in a locked office at a King's College London University campus. Audiotapes of any interviews will be also kept in a locked filing cabinet. Typed transcripts of the interviews/workshops will be stored on a University password-protected computer in a locked office at the University. Password-protected laptops may be used to transcribe interviews, these will be kept in the locked office when not in use. Only the research team, will have access to password protected computers/laptops which contain data for this research, in addition to locked filing cabinets. Once a participant has provided informed consent they will be assigned an ID number for the study which will be recorded on all study documents and will link the study documents to the participants name. The participant's name will not be recorded on any study document other than the informed consent form and Participant ID log.

The main burden will be the time commitment to completing the consent procedures and interview. Participants will be free to withdraw from the study at any point.

Insurance The study is sponsored by King's College London (KCL). The sponsor will, at all times, maintain adequate insurance in relation to the study through its professional indemnity (Clinical Trials) \& no fault compensation in respect of any claims arising as a result of negligence by its employees, brought by or on behalf of a study participant (with certain restrictions).

Publication and Dissemination Publication The research will be prepared for publication in peer reviewed journals and conference abstract submitted. All proposed publications will be discussed with the Sponsor.

Informing participants Study results will be automatically provided to participants.

Disclosure of Interests No competing interests to report.

03

Conditions studied

  • Type 2 Diabetes
  • Insulin
  • Education

Keywords

  • type 2 diabetes
  • insulin
  • education
  • self-management
  • application
  • digital health
  • qualitative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with type 2 diabetes starting insulin in hospital and the nurses who support them

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient Participants:

  • Adults aged 18 and above.
  • Adults with a type 2 diabetes diagnosis.
  • Adults who started insulin as an inpatient
  • Adults who understand and can communicate in English.
  • Adults who have the capacity to consent.

Nurse Participants:

  • Diabetes nurses working at King's College Hospital NHS Foundation Trust
  • Inpatient nurses caring for people with T2D

Exclusion criteria

Exclusion Criteria:

  • Adults who are not willing to participate.
  • Adults with severe physical/mental illness or cognitive dysfunction/significant learning difficulties.
  • Adults who are unable to speak or understand English.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • people with type 2 diabetes and nurses

    people with type 2 diabetes starting insulin in hospital and the nurses who support them

06

What researchers measure

Primary outcomes

  1. views of DIME

    We will interview people about the DIME web-based app to see what they think about it

    Time frame: participants interviewed on one occasion only, on day 1

07

Study locations

1 site
08

References and documents

Publications

  • Upsher R, Allen-Taylor M, Reece I, Chamley M, Ismail K, Forbes A, Winkley K. Experiences of Attending Group Education to Support Insulin Initiation in Type 2 Diabetes: A Qualitative Study. Diabetes Ther. 2020 Jan;11(1):119-132. doi: 10.1007/s13300-019-00727-7. Epub 2019 Nov 15. PubMed 31732858 ↗
  • Winkley K, Sorsa T, Tian Q, Reece I, Fitzgerald C, Chamley M, Ismail K, Forbes A, Upsher R. The diabetes insulin self-management education (DIME) intervention for people with type 2 diabetes starting insulin: a pilot feasibility randomised controlled trial. Pilot Feasibility Stud. 2023 May 26;9(1):89. doi: 10.1186/s40814-023-01318-x. PubMed 37237318 ↗
  • Tian Q, Upsher R, Winkley K. Systematic review and meta-analysis of diabetes specialist delivered insulin education for adults with type 2 diabetes in outpatient settings. Patient Educ Couns. 2022 Apr;105(4):835-842. doi: 10.1016/j.pec.2021.06.030. Epub 2021 Jul 2. PubMed 34272127 ↗

Related links

Individual participant data

Plan to share: No — This is qualitative interview data

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jun 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 18, 2026
StartEst.
Dec 10, 2026
Primary completionEst.
Jun 9, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945093
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 10, 2026 (estimated)
Primary completion
Jun 9, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Kirsty Winkley, PhD
Contact
kirsty.winkley@kcl.ac.uk
44 7879 625607

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion